

Applicant: Herbert T. Nagasawa et al.
U.S. Serial No.: 10/750,005
Filed: December 30, 2003
Page: 2

RECEIVED
CENTRAL FAX CENTER
JUL 11 2007

In the Claims:

For the Examiner's convenience, Applicants present all claims with status indicator in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c)(1).

Please cancel Claims 33-35, 38 and 39 without prejudice to pursue the subject matter of the claims in a continuation application to be filed in the future.

1. (CURRENTLY AMENDED) A method for reducing oxidative stress in a cell of a subject comprising contacting the cell with a sulfhydryl protected glutathione prodrug so as to reduce oxidative stress in a cell, wherein the sulfhydryl protected glutathione prodrug is L-CySSG, GSSMA, GSSME, S-Ac-GSH-OEt, a derivative thereof or a pharmaceutically acceptable salt thereof.
2. (ORIGINAL) The method of claim 1, wherein oxidative stress is caused by a toxic substance, a pathogen, ultraviolet light, physical injury and/or genetic disease.
3. (ORIGINAL) The method of claim 2, wherein the toxic substance is a drug, alcohol, metal ion, ultraviolet light or radiation.
4. (ORIGINAL) The method of claim 3, wherein the drug is acetaminophen, aminoglycoside antibiotic or a chemotherapeutic drug.
- 5-6. CANCELLED
7. CANCELLED
8. CANCELLED

Applicant: Herbert T. Nagasawa et al.
U.S. Serial No.: 10/750,005
Filed: December 30, 2003
Page: 3

9. (ORIGINAL) A method for prolonging drug therapy by decreasing the toxicity of a drug by the method of claim 1.

10. (ORIGINAL) A method for increasing a therapeutic dosage of a drug by decreasing the toxicity of the drug by the method of claim 1.

11-19. CANCELLED

20. (CURRENTLY AMENDED) A method for increasing glutathione levels in a cell comprising administering to a subject a sulfhydryl protected glutathione prodrug so as to increase glutathione levels in a cell, wherein the sulfhydryl protected glutathione prodrug is L-CySSG, GSSMA, GSSME, S-Ac-GSH-OEt, a derivative thereof or a pharmaceutically acceptable salt thereof.

21. (ORIGINAL) The method of claim 20, wherein increasing glutathione levels reduces injury caused by an infection, cardiovascular disease, genetic disease, physical injury, ophthalmic disease, cancer, inflammation, neuropathy, acute respiratory distress syndrome (ARDS), exposure to a toxic substance, exposure to ultraviolet light, exposure to radiation and/or decreased levels of glutathione.

22. CANCELLED

23-24. CANCELLED

25. (ORIGINAL) A method for prolonging drug therapy by decreasing the toxicity of a drug by the method of claim 20.

26. (ORIGINAL) A method for increasing a therapeutic dosage of a drug by decreasing the toxicity of the drug by the method of claim 20.

Applicant: Herbert T. Nagasawa et al.
U.S. Serial No.: 10/750,005
Filed: December 30, 2003
Page: 4

27-32. CANCELLED

33-35. CANCELLED

36-37. CANCELLED

38-39. CANCELLED

40-45. CANCELLED

46. (CURRENTLY AMENDED) A method for reducing hepatotoxicity comprising administering to a subject a sulfhydryl protected glutathione prodrug so as to reduce hepatotoxicity, wherein the sulfhydryl protected glutathione prodrug is L-CySSG, GSSMA, GSSME, S-Ac-GSH-OEt, a derivative thereof or a pharmaceutically acceptable salt thereof.

47. CANCELLED

48-49. CANCELLED

50. (ORIGINAL) A method for prolonging drug therapy by decreasing the toxicity of a drug by the method of claim 46.

51. (ORIGINAL) A method for increasing a therapeutic dosage of a drug by decreasing the toxicity of the drug by the method of claim 46.

52-104. CANCELLED